5. Johnson & Johnson

Total: $257.8 million
TV: $229 million
Magazine: $28.4 million
Newspaper: $11,400
Radio: $6,800

Johnson & Johnson's ($JNJ) pharma division led the way in revenue growth last year, and DTC ad spending soared along with it, according to Nielsen data. Its almost $260 million spend in 2014 was an increase of more than 120% over its 2013 spending. Growthwise, J&J came in second only to Sumitomo which backed a major push for Latuda's bipolar depression indication.

Next-gen blood thinner Xarelto was one reason for the J&J spending leap. But J&J is another case of advertising across a broad portfolio. Spending across a wide range of prescription drugs--mainly on TV and in print--added up. From psoriasis treatment Stelara (with TV ads featuring model CariDee English) to anti-inflammatory Remicade to newer hep C treatment Olysio, the J&J advertising portfolio includes about 30 prescription medications.

Overall, J&J's pharmaceuticals garnered $32.4 billion last year, making pharma the biggest of its divisions and marking 15% global growth year over year.

For 2015, J&J's new Type 2 diabetes drug Invokana already has a TV campaign and will likely continue the ad push as competition heats up in that space.

For more:
J&J's Invokana fends off new SGLT2 rivals to hit $278M in Q1
Opdivo, Praluent and LCZ-696 top a launch crop poised for $27B in sales
J&J tops 2013 journal-ad ranks with millions in print support for Invokana, Xarelto
J&J faces big spending, big rivals for new diabetes drug Invokana

5. Johnson & Johnson
Read more on

Suggested Articles

Despite outcomes data that left analysts less-than-enthused, Eli Lilly's Trulicity scored the FDA's nod to lower CV risks in a first-ever approval.

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.